Remission in rheumatoid arthritis patients treated with etanercept monotherapy: Clinical practice and clinical trial experience

Clinical and Experimental Rheumatology

Volumn 31, Issue 6, 2013, Pages 919-925

  Cannon, Grant W ^a   Wang, Brian C ^b   Park, Grace S ^c   Koenig, Andrew ^d   Collier, David H ^c   Keystone, Edward C ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b KForce Clinical Research   (United States)

^c AMGEN INC   (United States)

^d PFIZER INC   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Etanercept; RADIUS; Remission; Rheumatoid arthritis; TEMPO

Indexed keywords

ETANERCEPT; METHOTREXATE;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUSTRALIA; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HUMANS; IMMUNOGLOBULIN G; ISRAEL; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84892449972     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. ALAMANOS Y, DROSOS AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005; 4: 130-6.
2. CHOY EH, PANAYI GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
3. DROSSAERS-BAKKER KW, DE BUCK M, VAN ZEBEN D, ZWINDERMAN AH, BREEDVELD FC, HAZES JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42: 1854-60.
4. PINCUS T, SOKKA T, WOLFE F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 2001; 44: 1234-6.
5. WATSON DJ, RHODES T, GUESS HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30: 1196-202.
6. American College of Rheumatology Subcommittee on Rheumatoid ArthritisGuidelines: Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46: 328-46.
7. SMOLEN JS, LANDEWÉ R, BREEDVELD FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
8. SAAG KG, TENG GG, PATKAR NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
9. Enbrel®, (etanercept). Full Prescribing Information, Immunex Corporation, Thousand Oaks, CA, 2011.
10. BATHON JM, MARTIN RW, FLEISCHMANN RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
11. KEYSTONE EC, SCHIFF MH, KREMER JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 353-63.
12. KLARESKOG L, van der HEIJDE D, de JAGER JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
13. MORELAND LW, SCHIFF MH, BAUMGART-NER SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
14. WEINBLATT ME, KREMER JM, BANKHURST AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
15. GIBOFSKY A, PALMER WR, GOLDMAN JA, et al. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. Curr Med Res Opin 2006; 22: 169-83.
16. WEAVER AL, LAUTZENHEISER RL, SCHIFF MH, et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006; 22: 185-98.
17. van der HEIJDE D, KLARESKOG L, LAN-DEWÉ R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 3928-39.
18. KATCHAMART W, JOHNSON S, LIN HJ, PHUMETHUM V, SALLIOT C, BOMBARDIER C. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken) 2010; 62: 1128-43.
19. KEYSTONE E, FREUNDLICH B, SCHIFF M, LI J, HOOPER M. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. J Rheumatol 2009; 36: 522-31.
20. VERSCHUEREN P, ESSELENS G, WESTHOVENS R. Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol 2009; 38: p.166-72.
21. VAZQUEZ I, GRAELL E, GRATACÓS J, et al. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. Clin Exp Rheumatol 2007; 25: 231-8.
22. RAFFEINER B, et al. Fast remission response to etanercept predicts maintenance of clinical and radiological remission in rheumatoid arthritis [abstract no. Thu0218]. Ann Rheum Dis 2011; 70 (Suppl. 3): 250.
23. ZINK A, ASKLING J, DIXON WG, KLARESKOG L, SILMAN AJ, SYMMONS DP. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009; 68: 1240-6.
24. RANGANATH VK, PAULUS HE, ONOFREI A, et al. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. J Rheumatol 2008; 35: 1966-71.
25. ASKLING J, FORED CM, GEBOREK P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006; 65: 707-12.
26. HYRICH KL, WATSON KD, ISENBERG DA, SYMMONS DP, et al. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) 2008; 47: 1441-3.
27. LISTING J, STRANGFELD A, RAU R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther 2006; 8: R66.